The invention relates to a new pharmacotherapeutical strategy, to an anti-stress, anti-impairment and anti-aging
drug and to a process for its manufacturing. The
drug has an etio-pathogenic and homeostatic action, was preclinically tested and clinically checked up in geriatric, neurologic, psychiatric and stress-dependent
pathology. The
drug achieves a synergistic biological, neurometabolic and
cell-trophic composition, being elaborated by the association of the following active principles: a) against oxidative and catabolic stress;
methionine with aminoethanol phenoxyacetates and / or aminoethyl phenoxyacetamides; b) against anabolic stress; hydroxopyrimidine carboxylates and / or oxopyrrolidine acetamides with
potassium,
zinc and
lithium; c) vasodilative and normolipidemic; nicotinic,
alcohol and / or acid, or its derivatives, with
magnesium and
iodine; d) energo-active and e) anti-toxic; aspartate;
fructose;
vitamin B1;
vitamin B6; monoacid
phosphate and
sulfate. The process for manufacturing the drug stipulates; a) pharmaceutical preparation in two complementary types of capsules or
coated tablets, gastrosoluble and enterosoluble, the last being
enteric coated; b) prolonged-release of vasodilator from the enterosoluble unit.